These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Analytical and clinical evaluation of the Bio-Rad HPLC kit for measurement of type I collagen cross links.
    Author: Srivastava AK, Libanati C, Oberrauch W, Leenings J, Greenwald M, Baylink DJ.
    Journal: J Bone Miner Metab; 2003; 21(3):134-44. PubMed ID: 12720047.
    Abstract:
    The measurement of hydroxylysylpyridinoline (PYD) and lysylpyridinoline (DPD), the degradation products of type I collagen, by manual HPLC assay posed practical difficulties. The present study was undertaken to evaluate the first commercially available HPLC kit, which provides a convenient substitute for cumbersome classical HPLC methods. The HPLC procedure is based on an improved sample clean-up chromatography, convenient ready-to-use HPLC reagents, and quicker isocratic elution of PYR and DPD on reverse-phase analytical column. The analytical parameters assessed include sensitivity, within- and between-assay variation, method comparison, recoveries, and interference. Clinical evaluation included discriminatory power of PYD and DPD and response to treatment of osteoporosis patients with Alendronate. DPD and PYD concentrations showed linear ( r(2) > 0.99) response between 10-400 pmol/ml and 75-4000 pmol/ml, respectively. The average within-assay imprecision, over a range of clinically relevant cross-links concentrations, was CV < 7% ( n = 30). The total imprecision ( n = 35 days), by ANOVA, for PYD and DPD was CV < 7.5% and CV < 10%, respectively. Average spike recovery was 95.4% +/- 6.5%. Comparison with the historical HPLC method exhibited a close correlation ( r values between 0.87 and 0.91, P < 0.0001). Creatinine-corrected DPD in postmenopausal ( Z score = 2.4, P < 0.05, n = 17) and osteoporotic ( Z score = 3.0, P < 0.01, n = 29) women were 44% and 64% higher, respectively, compared to premenopausal samples ( n = 15). Similarly, PYD concentration was 26% and 54% higher in postmenopausal and postmenopausal osteoporotic women, respectively. There was a 47% ( P < 0.001) decrease in DPD concentration ( n = 16), and a 30% decrease in PYD concentration after 90 days of treatment of osteoporotic patients with Alendronate. DPD concentration correlated with N-telopeptide with an r value of 0.69 ( n = 67, P < 0.0001). The reported kit method is substantially simpler and precise than the manual method. DPD concentrations determined by the current method reaffirm the clinical value in identifying increased bone resorption in pathological conditions and monitoring response to antiresorptive therapy.
    [Abstract] [Full Text] [Related] [New Search]